Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19/CD28 bispecific antibody RO7443904

A bispecific antibody directed against both the tumor-associated antigen (TAA) CD19 and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD28 bispecific antibody RO7443904 targets and binds to both CD28 expressed on T cells and CD19 expressed on tumor cells, which crosslinks the T cells to the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against the CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
Synonym:anti-CD19/anti-CD28 bispecific antibody RO7443904
anti-CD28/anti-CD19 bispecific antibody RO7443904
CD19 x CD28 bispecific antibody RO7443904
Code name:RG 6333
RG-6333
RG6333
RO 7443904
RO-7443904
RO7443904
Search NCI's Drug Dictionary